The FDA has proposed ending the use of a common ingredient found in many cold and allergy medicines — and some pharmacies ...

Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

Some cases expand on earlier initiatives, like the Valsartan cases. The theory against these was launched from the Zantac ...

The FDA announced a proposal to remove oral phenylephrine – a common ingredient in many popular over-the-counter decongestants – from the market, citing evidence that it doesn't work.

With Donald Trump all set to become US president, Indian exporters may face high customs duties for goods like automobiles, textiles and pharmaceuticals if the new US administration decides to pursue ...

It's still October and Amazon just wrapped up its fall Prime Day sale earlier this month, but it's never too early to start looking at Black Friday deals. Amazon offers one of the largest Black ...

Ozempic, Wegovy considered ‘available’ after more than 2 years in shortage - Demand for the popular weight loss and diabetes ...

And as recently announced, we have expedited retiring the risk for Zantac ... U.S., I think we -- there's still 80% of those that ACIP, have said this vaccine is available to, who are not yet ...

GSK shares fell on Wednesday after the group's vaccine sales continued to disappoint in the third quarter. The drugmaker saw weaker-than-expected demand for its respiratory syncytial virus (RSV ...

The UK’s second-biggest pharmaceutical firm still saw 2% sales growth across the business after ... of thousands of lawsuits in the US over its discontinued heartburn drug Zantac earlier in October.

Although interest rates have dropped slightly at many banks after the Fed’s half-point September rate cut, it’s still an excellent ... the best CD rates available nationwide are around or ...

Two new COVID-19 vaccines targeting the KP. 2 variant of the virus have been made available for all Ontarians starting Monday, after weeks of only being open to high-risk and priority populations.